Skip to main content
Top
Published in: Breast Cancer Research 1/2004

01-02-2004 | Erratum

Erratum to: Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression

Authors: Martin C Abba, Jeffery A Drake, Kathleen A Hawkins, Yuhui Hu, Hongxia Sun, Cinitia Notcovich, Sally Gaddis, Aysegul Sahin, Keith Baggerly, C Marcelo Aldaz

Published in: Breast Cancer Research | Issue 1/2004

Login to get access

Excerpt

A correction to Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression by Martin C Abba, Jeffery A Drake, Kathleen A Hawkins, Yuhui Hu, Hongxia Sun, Cintia Notcovich, Sally Gaddis, Aysegul Sahin, Keith Baggerly and C Marcelo Aldaz. …
Literature
1.
go back to reference Abba MC, Drake J, Hawkins K, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM: Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 2004, 6: R499-R513. 10.1186/bcr899.CrossRefPubMedPubMedCentral Abba MC, Drake J, Hawkins K, Hu Y, Sun H, Notcovich C, Gaddis S, Sahin A, Baggerly K, Aldaz CM: Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression. Breast Cancer Res. 2004, 6: R499-R513. 10.1186/bcr899.CrossRefPubMedPubMedCentral
Metadata
Title
Erratum to: Transcriptomic changes in human breast cancer progression as determined by serial analysis of gene expression
Authors
Martin C Abba
Jeffery A Drake
Kathleen A Hawkins
Yuhui Hu
Hongxia Sun
Cinitia Notcovich
Sally Gaddis
Aysegul Sahin
Keith Baggerly
C Marcelo Aldaz
Publication date
01-02-2004
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 1/2004
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr990

Other articles of this Issue 1/2004

Breast Cancer Research 1/2004 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine